-
Encorafenib, sold
under the
brand name Braftovi, is a
medication used for the
treatment of
certain melanoma cancers. It is a
small molecule BRAF inhibitor...
- cancers. In June 2018 it was
approved by the FDA in
combination with
encorafenib for the
treatment of
patients with
unresectable or
metastatic BRAF V600E...
-
Binimetinib (MEK162),
approved by the FDA in June 2018 in
combination with
encorafenib for the
treatment of
patients with
unresectable or
metastatic BRAF V600E...
-
inhibitor -
Approved 2020,
owned by
Seagen (Seattle Genetics)
BRAFTOVI (
Encorafenib) - BRAF
inhibitor -
Approved 2018,
acquired by
Pfizer KRAZATI (Adagrasib)...
- L01EB11
Aumolertinib L01EC01
Vemurafenib L01EC02
Dabrafenib L01EC03
Encorafenib L01ED01
Crizotinib L01ED02
Ceritinib L01ED03
Alectinib L01ED04 Brigatinib...
- inhibitor.
Other Raf
inhibitors include SB590885, PLX4720, XL281, RAF265,
encorafenib, dabrafenib, and vemurafenib. Some MEK
inhibitors include cobimetinib...
- In June 2018, the FDA
approved the
combination of a BRAF
inhibitor encorafenib and a MEK
inhibitor binimetinib for the
treatment of un-resectable or...
- HER1/EGFR and HER2/neu
Lapatinib Neratinib Tucatinib BRAF
Dabrafenib Encorafenib Vemurafenib RTK
class III: C-kit and
PDGFR (Avapritinib
Axitinib Masitinib...
- candidates; the MEK
inhibitor binimetinib (MEK 162) and the BRAF
inhibitor encorafenib (LGX818), for $85 million. In addition, the
company sold its RNAi portfolio...
- doi:10.2147/cmar.s33979. PMC 3421468. PMID 22904643. "FDA
approves Encorafenib and
Binimetinib in
combination for
unresectable or
metastatic melanoma...
